Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2011. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details specific share acquisitions by nine individuals on November 9, 2011, executed through the Company's Share Reward Plan at a price of 1382.45 pence per Ordinary share. Each individual acquired:
- 9 Ordinary shares under the partnership element (personal contribution).
- 9 Ordinary shares under the matching element (Company contribution).
The individuals involved are Mr. A P Witty, Mr. S Dingemans, Mr. S M Bicknell, Mr. E J Gray, Mr. D S Redfern, Ms. C Thomas, Mr. P C Thomson, Dr. P J T Vallance, and Mrs. V A Whyte.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the aforementioned share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of 1382.45 pence against market data for November 9, 2011.
- Confirm the total number of shares acquired by each listed director (18 shares per person: 9 personal + 9 matched).
- Review the terms of the Company's Share Reward Plan to understand the matching contribution structure.